This PTEN/ARID4B/PI3K signalling axis identifies a novel player in the PTEN-mediated suppression of the PI3K pathway and provides a new opportunity to design novel therapeutics to target this axis to promote the tumour suppressive functions of PTEN. This evidence concerns the gene PTEN and neoplasm.